1. Home
  2. QDEL vs NEO Comparison

QDEL vs NEO Comparison

Compare QDEL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$10.73

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$8.40

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
NEO
Founded
1979
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2022
2008

Fundamental Metrics

Financial Performance
Metric
QDEL
NEO
Price
$10.73
$8.40
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
$28.25
$13.38
AVG Volume (30 Days)
2.4M
2.2M
Earning Date
05-05-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
N/A
EPS
N/A
N/A
Revenue
$2,730,200,000.00
N/A
Revenue This Year
$3.51
$10.63
Revenue Next Year
$3.86
$9.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.92
$4.72
52 Week High
$35.58
$13.74

Technical Indicators

Market Signals
Indicator
QDEL
NEO
Relative Strength Index (RSI) 39.34 46.83
Support Level $10.39 $7.50
Resistance Level $12.85 $8.84
Average True Range (ATR) 0.92 0.55
MACD 0.15 -0.07
Stochastic Oscillator 27.30 10.44

Price Performance

Historical Comparison
QDEL
NEO

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: